Skip to content
stoqly
en

Popular

All languages

Figures come from SEC filings, which are in English. Company and industry names stay as filed.

$ USD

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 23, 2026.

Cogent Biosciences, Inc.

COGT Nasdaq Pharmaceutical Preparations Financials FY2017โ€“FY2025

Last close ยท Oct 23, 2026

$31.21

0.3%
Compare
Revenue Total sales reported in the income statement.
โ€”
vs prior year
Operating margin Operating income as a share of revenue.
โ€”
Net income Profit after all expenses, interest and tax.
โˆ’$329M
Free cash flow Cash from operations minus capital spending.
โˆ’$266M
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
โ€”
Market cap Last close times the latest diluted share count, so it is approximate.
$5.3B
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
โ€”
On โˆ’$2.16 EPS (TTM)

What Cogent Biosciences, Inc. does

No business description yet.

Legal name
Cogent Biosciences, Inc.
Fiscal year ends
December 31, 2025
Latest annual report
10-K ยท Feb 17, 2026
Accession ยท CIK
0001193125-26-053334
0001622229

Revenue and margins

Cogent Biosciences, Inc. had โ€” of revenue in fiscal 2025.

Revenue
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was โˆ’$266M in fiscal 2025, โ€” of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Cogent Biosciences, Inc. returned โ€” to shareholders in fiscal 2025. The diluted share count rose 24.1%.

Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Balance sheet

Cash, debt and the ratios that show how comfortably Cogent Biosciences, Inc. can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $220M$259M$266M$287M$901M
Debt incl. finance leases โ€”โ€”โ€”$0.0M$223M
Debt / equity โ€”โ€”โ€”0.0x0.4x
Interest coverage โ€”โ€”โ€”โ€”โˆ’108.9x
Current ratio 13.0x9.9x7.1x5.3x14.2x
Quick ratio 13.0x9.9x7.1x5.3x14.2x
Total assets $232M$301M$313M$328M$938M
Total liabilities $17.9M$45.1M$55.6M$71.6M$301M
Shareholders' equity $214M$256M$258M$256M$636M
Net debt (โˆ’ = net cash) โ€”โ€”โ€”โˆ’$287Mโˆ’$678M

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โ€œPlanโ€ marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

โ€”

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8โ€“9 is strong, 0โ€“2 weak.

TestFY17FY18FY19FY20FY21FY22FY23FY24FY25
Net income is positive โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ•
Cash from operations is positive โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ•
Return on assets rose โ€” โœ“ โœ• โœ“ โœ• โœ• โœ• โœ• โœ“
Cash from operations exceeds net income โœ• โœ“ โœ• โœ“ โœ“ โœ“ โœ“ โœ“ โœ“
Debt fell relative to assets โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€” โœ•
Current ratio rose โ€” โœ• โœ• โœ“ โœ• โœ• โœ• โœ• โœ“
Share count didn't rise โ€” โœ• โœ“ โœ• โœ• โœ• โœ• โœ• โœ•
Gross margin rose โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€”
Revenue rose relative to assets โ€” โœ• โœ“ โœ• โ€” โ€” โ€” โ€” โ€”
F-score โ€” / 32 / 72 / 73 / 7โ€” / 6โ€” / 6โ€” / 6โ€” / 63 / 7
Accruals ratio 0.7%โˆ’3.0%14.3%โˆ’25.9%โˆ’5.6%โˆ’8.1%โˆ’12.6%โˆ’15.0%โˆ’10.2%
Altman Z'' โˆ’5.280.43โˆ’7.0316.4412.373.39โˆ’1.01โˆ’5.631.62

9 years of figures

Amounts in USD. Hover a ratioโ€™s name for its definition.

Download CSV
Fiscal yearFY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $8.4M $9.7M $22.5M $7.9M โ€” โ€” โ€” โ€” โ€”
Research and development $29.8M $38.3M $43.7M $25.7M $55.9M $122M $174M $233M $270M
Operating income โˆ’$26.2M โˆ’$36.0M โˆ’$32.2M โˆ’$82.2M โˆ’$75.6M โˆ’$148M โˆ’$208M โˆ’$276M โˆ’$333M
Interest expense โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€” $3.1M
Income tax โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€” $0.0M
Net income โˆ’$25.5M โˆ’$34.5M โˆ’$31.8M โˆ’$74.8M โˆ’$72.3M โˆ’$140M โˆ’$192M โˆ’$256M โˆ’$329M
Net income to common โˆ’$25.6M โˆ’$34.5M โˆ’$31.8M โˆ’$179M โˆ’$72.3M โˆ’$140M โˆ’$192M โ€” โ€”
Diluted EPS โˆ’$2.51 โˆ’$1.39 โˆ’$4.18 โˆ’$16.17 โˆ’$1.87 โˆ’$1.73 โˆ’$1.94 โˆ’$1.94 โˆ’$2.16
Diluted shares 0.01B 0.02B 0.01B 0.01B 0.04B 0.06B 0.08B 0.10B 0.13B
Cash flow
Cash from operations โˆ’$25.8M โˆ’$32.5M โˆ’$41.5M โˆ’$35.9M โˆ’$58.8M โˆ’$119M โˆ’$154M โˆ’$208M โˆ’$264M
Capital expenditure $0.9M $0.5M $0.0M โ€” $1.7M $6.9M $2.8M $0.6M $1.6M
Free cash flow โˆ’$26.7M โˆ’$33.0M โˆ’$41.5M โ€” โˆ’$60.5M โˆ’$126M โˆ’$156M โˆ’$208M โˆ’$266M
Depreciation and amortization $1.2M $1.3M $1.3M $0.7M $0.1M $0.8M $2.3M $2.5M $2.6M
Stock-based compensation $1.3M $3.1M $3.2M $6.0M $11.7M $18.4M $30.6M $39.7M $46.1M
Balance sheet
Cash and short-term investments $41.0M $55.7M $37.4M $242M $220M $259M $266M $287M $901M
Total debt โ€” โ€” โ€” โ€” โ€” โ€” โ€” $0.0M $223M
Current assets $42.4M $81.0M $40.6M $245M $223M $265M $271M $296M $910M
Current liabilities $11.2M $24.9M $13.2M $13.1M $17.1M $26.8M $38.2M $55.7M $64.0M
Property and equipment, net $4.1M $3.3M $1.9M $0.1M $1.7M $7.8M $8.3M $6.5M $5.5M
Total assets $49.1M $85.9M $49.4M $251M $232M $301M $313M $328M $938M
Total liabilities $20.8M $25.7M $17.7M $16.2M $17.9M $45.1M $55.6M $71.6M $301M
Shareholders' equity โˆ’$48.8M $60.2M $31.8M $235M $214M $256M $258M $256M $636M
Margins
Operating margin โˆ’312.8% โˆ’369.9% โˆ’143.0% โˆ’1,044.3% โ€” โ€” โ€” โ€” โ€”
EBITDA margin โˆ’298.8% โˆ’356.3% โˆ’137.3% โˆ’1,035.2% โ€” โ€” โ€” โ€” โ€”
Net margin โˆ’304.9% โˆ’354.8% โˆ’141.5% โˆ’950.4% โ€” โ€” โ€” โ€” โ€”
FCF margin โˆ’319.9% โˆ’339.4% โˆ’184.7% โ€” โ€” โ€” โ€” โ€” โ€”
Returns
Return on capital employed โˆ’69.0% โˆ’59.0% โˆ’89.0% โˆ’34.6% โˆ’35.1% โˆ’54.0% โˆ’75.6% โˆ’101.4% โˆ’38.2%
Return on equity โ€” โˆ’606.5% โˆ’69.2% โˆ’56.2% โˆ’32.2% โˆ’59.7% โˆ’74.9% โˆ’99.5% โˆ’73.7%
Return on assets โˆ’51.9% โˆ’51.1% โˆ’47.0% โˆ’49.8% โˆ’29.9% โˆ’52.6% โˆ’62.6% โˆ’79.8% โˆ’52.0%
Return on tangible equity โ€” โˆ’57.4% โˆ’100.2% โˆ’76.4% โˆ’33.7% โˆ’54.8% โˆ’74.6% โˆ’99.8% โˆ’51.7%
Growth
Revenue growth โ€” 16.4% 131.1% โˆ’65.0% โ€” โ€” โ€” โ€” โ€”
Share count change โ€” 144.3% โˆ’69.4% 45.4% 249.5% 51.7% 35.6% 30.4% 24.1%
Financial health
Debt / equity โ€” โ€” โ€” โ€” โ€” โ€” โ€” 0.0x 0.4x
Interest coverage โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€” โˆ’108.9x
Current ratio 3.8x 3.2x 3.1x 18.7x 13.0x 9.9x 7.1x 5.3x 14.2x
Quick ratio 3.8x 3.2x 3.1x 18.7x 13.0x 9.9x 7.1x 5.3x 14.2x
Capital allocation
Capex / revenue 10.9% 5.6% 0.1% โ€” โ€” โ€” โ€” โ€” โ€”
Stock comp / revenue 16.0% 31.7% 14.4% 76.4% โ€” โ€” โ€” โ€” โ€”
Quality scores
Piotroski F-score โ€” 2.0 2.0 3.0 โ€” โ€” โ€” โ€” 3.0
Altman Z'' โˆ’5.3 0.4 โˆ’7.0 16.4 12.4 3.4 โˆ’1.0 โˆ’5.6 1.6
Accruals ratio 0.7% โˆ’3.0% 14.3% โˆ’25.9% โˆ’5.6% โˆ’8.1% โˆ’12.6% โˆ’15.0% โˆ’10.2%

Source: SEC EDGAR XBRL filings (CIK 0001622229). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ€” not investment advice. Check the original filings before relying on any figure.

โ†‘ โ†“ to move ยท โ†ต to open